Table 3.
Summary of reports of treatment with imatinib mesylate for dermatofibrosarcoma protuberans
| NO. OF PATIENTS | DISEASE STAGE | CYTOGENETICS | DAILY DOSE | DURATION OF THERAPY (MONTHS) | RESPONSE |
|---|---|---|---|---|---|
| (N=2)18 | Metastasis to lung | Complex | 400mg | 1.0 | Transient |
| (N=1)29 | Paravertebral metastasis | Complex [t(17;22) not identified] | 800mg | 4.0 | Complete |
| (N=10)19 | Locally advanced DFSP (n=8) and metastatic DFSP (n=2) | 8 with t(17;22); 2 complex karyotypes | 800mg | 0.75–25 | 2/10 partial response (>50% reduction in tumor size); 4/10 complete response; 1/10 stable |
| (N=24)6 | Metastasis, DFSP-FS, inoperable | PDGFβ rearrangement, t(17;22) | 400mg, 800mg | 48 weeks | 11/24 partial response; 4/24 progressive disease |
| (N=15)7 | Metastasis (n=6), DFSP-FS (n=7) | COL1A1-PDGFβ | 400mg, 800mg | 3–8 (3.3) | 10/15 partial response; 2/15 stable; 3/15 progressed |